Search

Your search keyword '"M Trauner"' showing total 287 results
Start Over Author "M Trauner" Topic business.industry
287 results on '"M Trauner"'

2. Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen

Author

M. Trauner, Rodrig Marculescu, I Villesen, Bernhard Scheiner, D Leeming, Philipp Schwabl, Benedikt Simbrunner, Matthias Pinter, AF Stättermayer, Peter Quehenberger, Thomas Reiberger, Mattias Mandorfer, M Karsdal, David Bauer, and Rafael Paternostro

Subjects
medicine.medical_specialty, Endocrinology, Antigen, Von Willebrand factor, biology, business.industry, Internal medicine, biology.protein, medicine, Portal hypertension, Protein precursor, business, medicine.disease
Published
2021

3. The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Author

Bernhard Scheiner, M. Trauner, Lorenz Balcar, Tobias Meischl, Matthias Pinter, Christian Müller, Thomas Reiberger, Katharina Pomej, and Mattias Mandorfer

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Hepatocellular carcinoma, Sorafenib treatment, Medicine, In patient, business, medicine.disease, Cancer prognosis
Published
2021

4. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease

Author

M. Trauner, Mattias Mandorfer, Lorenz Balcar, Peter Quehenberger, AF Stättermayer, Bernhard Scheiner, RJ Nussbaumer, Rafael Paternostro, Matthias Pinter, Georg Semmler, Benedikt Simbrunner, Lukas Hartl, Thomas Reiberger, Douglas C. Bauer, Katharina Pomej, Mathias Jachs, and J Weinzierl

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Clinical significance, business, Chronic liver disease, medicine.disease, Gastroenterology, Von Willebrand factor Antigen
Published
2021

5. Acute haemodynamic response to intravenous propranolol predicts decompensation and mortality in patients with cirrhosis

Author

M. Trauner, Benedikt Simbrunner, Douglas C. Bauer, Mattias Mandorfer, Mathias Jachs, AF Stättermayer, Thomas Reiberger, Rafael Paternostro, Lukas Hartl, Bernhard Scheiner, Philipp Schwabl, and Benedikt Silvester Hofer

Subjects
medicine.medical_specialty, Cirrhosis, Haemodynamic response, business.industry, Internal medicine, Cardiology, medicine, In patient, Decompensation, Propranolol, medicine.disease, business, medicine.drug
Published
2021

6. Covered transjugular intrahepatic portosystemic shunt improves hypersplenism-associated cytopenia in cirrhosis

Author

M. Trauner, Thomas Reiberger, Benedikt Simbrunner, Maria Schoder, Florian Wolf, Mattias Mandorfer, Lukas Hartl, F Karnel, C Vierziger, Douglas C. Bauer, T Grünberger, TA Müllner-Bucsics, Katharina Lampichler, and Mathias Jachs

Subjects
medicine.medical_specialty, Cytopenia, Cirrhosis, business.industry, Internal medicine, medicine.medical_treatment, Medicine, business, medicine.disease, Gastroenterology, Transjugular intrahepatic portosystemic shunt
Published
2021

7. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease

Author

Georg Semmler, M. Trauner, Lukas Hartl, Bernhard Scheiner, Peter Quehenberger, Matthias Pinter, Thomas Reiberger, Douglas C. Bauer, Mattias Mandorfer, AF Stättermayer, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, and Rafael Paternostro

Subjects
medicine.medical_specialty, Von Willebrand factor, biology, business.industry, Internal medicine, medicine, biology.protein, Chronic liver disease, medicine.disease, Outcome prediction, business, Gastroenterology
Published
2021

8. Covered TIPS improves renal function in patients with cirrhosis and ascites

Author

JP Jonas, Mattias Mandorfer, T Grünberger, Maria Schoder, Lukas Hartl, K Schönhofer, Thomas Reiberger, M. Trauner, F Karnel, TA Müllner-Bucsics, Douglas C. Bauer, Florian Wolf, Mathias Jachs, and Josef Karner

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Internal medicine, Ascites, medicine, Renal function, In patient, medicine.symptom, medicine.disease, business, Gastroenterology
Published
2021

9. Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease

Author

M. Trauner, RJ Nussbaumer, Mathias Jachs, Lorenz Balcar, Ton Lisman, Georg Semmler, Bernhard Scheiner, AF Stättermayer, Benedikt Simbrunner, Matthias Pinter, J Weinzierl, Peter Quehenberger, Douglas C. Bauer, Rafael Paternostro, Thomas Reiberger, Mattias Mandorfer, and Lukas Hartl

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology, Protein C, medicine.drug
Published
2021

11. Increasing ACE activity in liver disease impacts on fibrinolysis and inflammation - a potential link to COVID-19

Author

Bernhard Scheiner, David Bauer, Mathias Jachs, Thomas Reiberger, M. Trauner, Benedikt Simbrunner, Georg Semmler, Lukas Hartl, and Mattias Mandorfer

Subjects
Liver disease, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Immunology, Fibrinolysis, Medicine, Inflammation, Ace activity, medicine.symptom, business, medicine.disease
Published
2021

12. Safety and efficacy of direct oral anticoagulants (DOACs) in Budd-Chiari Syndrome (BCS) - an Austrian multicenter study

Author

Bernhard Scheiner, Mattias Mandorfer, M. Trauner, Elmar Aigner, David Bauer, S Hametner-Schreil, Georg Semmler, S Bartl, R Schöfl, A Lindorfer, Katharina Pomej, Thomas Reiberger, H Hofer, Benedikt Simbrunner, S Gensluckner, Lorenz Balcar, and Christian Datz

Subjects
Pediatrics, medicine.medical_specialty, Multicenter study, business.industry, Budd–Chiari syndrome, medicine, medicine.disease, business
Published
2021

13. Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease

Author

Ton Lisman, M. Trauner, Benedikt Simbrunner, Peter Quehenberger, Bernhard Scheiner, Jeannette Becker, Teresa Binter, Thomas Reiberger, David Bauer, Katharina Pomej, Mattias Mandorfer, Matthias Pinter, Lorenz Balcar, Georg Semmler, and Lukas Hartl

Subjects
Liver disease, medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, medicine.disease, business, Gastroenterology
Published
2021

14. Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease

Author

Joan Genescà, Philipp Schwabl, Thomas Reiberger, AF Stättermayer, Sergio Rodríguez-Tajes, Peter Ferenci, Benedikt Simbrunner, Lopez S Alonso, David Chromy, Mattias Mandorfer, Sabela Lens, M. Trauner, David Bauer, EL Meyer, ML Manzano, Alberto Zanetto, Rafael Bañares, Michael Schwarz, Francesco Paolo Russo, Karin Kozbial, M Gschwantler, S Hametner-Schreil, R Schöfl, Matthias Pinter, Mònica Pons, Georg Semmler, and Bernhard Scheiner

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Hepatocellular carcinoma, Virologic response, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology
Published
2021

15. Predicting the outcome of patients with hepatocellular carcinoma treated with immunotherapy - the CRAFITY score

Author

M. Trauner, F Finkelmeier, MP Ebert, Christian Müller, Kornelius Schulze, F Hucke, Lorenz Balcar, Thomas Reiberger, Pompilia Radu, Katharina Pomej, Fabian Kütting, SDe Dossa, D Waldschmidt, Alexander Siebenhüner, Bernhard Scheiner, Andreas Teufel, Nuh N. Rahbari, O Waidmann, Sandra Koch, David J. Pinato, S Spahn, Tobias Meischl, Matthias Pinter, Martha M. Kirstein, and Joachim C. Mertens

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Hepatocellular carcinoma, medicine, Immunotherapy, medicine.disease, business, Outcome (game theory)
Published
2021

16. Risk evaluation for acute kidney injury and acute-on-chronic liver failure via a blood-based biomarker panel in patients with cirrhosis

Author

Lukas Hartl, Georg Semmler, David Bauer, Mathias Jachs, Mattias Mandorfer, Benedikt Simbrunner, Thomas Reiberger, and M. Trauner

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Blood based biomarkers, Internal medicine, Acute kidney injury, Medicine, Acute on chronic liver failure, In patient, business, medicine.disease, Gastroenterology, Risk evaluation
Published
2021

17. NSBB-associated VWF-decreases in decompensated cirrhosis indicate a reduced risk of further decompensation, ACLF, and death

Author

Lukas Hartl, Mattias Mandorfer, Ernst Eigenbauer, Douglas C. Bauer, M. Trauner, AF Stättermayer, Mathias Jachs, Matthias Pinter, Philipp Schwabl, Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Bernhard Scheiner, and Peter Quehenberger

Subjects
medicine.medical_specialty, Reduced risk, business.industry, Internal medicine, Cardiology, medicine, Decompensation, Decompensated cirrhosis, business
Published
2021

20. Association of Adenoma Detection Rate and Adenoma Characteristics With Colorectal Cancer Mortality After Screening Colonoscopy

Author

A Hinterberger, M. Trauner, Andreas A. Kammerlander, Monika Ferlitsch, Elisabeth A Waldmann, B Majcher, Michael Bretthauer, Irina Gessl, and D Penz

Subjects
Adenoma, medicine.medical_specialty, Hepatology, medicine.diagnostic_test, business.industry, Colorectal cancer, Incidence (epidemiology), Mortality rate, Hazard ratio, Gastroenterology, Colonoscopy, Lower risk, medicine.disease, digestive system diseases, Confidence interval, Risk Factors, Internal medicine, medicine, Humans, business, Colorectal Neoplasms, Early Detection of Cancer
Abstract

The adenoma detection rate (ADR) and characteristics of previously resected adenomas are associated with colorectal cancer (CRC) incidence and mortality. However, the combined effect of both factors on CRC mortality is unknown.Using data of the Austrian quality assurance program for screening colonoscopy, we evaluated the combined effect of ADR and lesion characteristics on subsequent risk for CRC mortality. We analyzed mortality rates for individuals with low-risk adenomas (1-2 adenomas10 mm), individuals with high-risk adenomas (advanced adenomas or ≥3 adenomas), and after negative colonoscopy (negative colonoscopy or small hyperplastic polyps) performed by endoscopists with an ADR25% compared with ≥25%. Cox regression was used to determine the association of combined risk groups with CRC mortality, adjusted for age and sex.We evaluated 259,885 colonoscopies performed by 361 endoscopists. A total of 165 CRC-related deaths occurred during the follow-up period, up to 12.2 years. In all risk groups, CRC mortality was higher when colonoscopy was performed by an endoscopist with an ADR25%. Compared with negative colonoscopy with an ADR ≥25%, CRC mortality was similar for individuals with low-risk adenomas irrespective of ADR (for ADR ≥25%: adjusted hazard ratio [HR], 1.22; 95% confidence interval [CI], 0.59-2.49; for ADR25%: adjusted HR, 1.25; 95% CI, 0.64-2.43) and after negative colonoscopy with ADR25% (adjusted HR, 1.27; 95% CI, 0.81-2.00). Individuals with high-risk adenomas were at significantly higher risk for CRC death if colonoscopy was performed by an endoscopist with an ADR25% (adjusted HR, 2.25; 95% CI, 1.18-4.31) but not if performed by an endoscopist with an ADR ≥25% (adjusted HR, 1.35; 95% CI, 0.61-3.02).Our study adds important evidence for mandatory assessment and monitoring of performance quality in screening colonoscopy. High-quality colonoscopy was associated with a lower risk for CRC death, and the impact of ADR was strongest for individuals with high-risk adenomas.

Published
2020

21. Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with PBC who did not achieve the POISE criteria

Author

D.E.J. Jones, Gideon M. Hirschfield, M. Trauner, Marco Carbone, Andreas E. Kremer, Alexander Liberman, Bettina E. Hansen, L Mac Conell, and E. Smoot Malecha

Subjects
medicine.medical_specialty, chemistry.chemical_compound, chemistry, business.industry, Internal medicine, OPEN LABEL TREATMENT, medicine, Obeticholic acid, In patient, business, Gastroenterology, Durability
Published
2020

24. Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

Author

Philipp Schwabl, Bernhard Scheiner, Douglas C. Bauer, Thomas Reiberger, Arnulf Ferlitsch, Peter Ferenci, Markus Peck-Radosavljevic, M. Trauner, Heinz Zoller, AF Stättermayer, Mattias Mandorfer, Rafael Paternostro, and Benedikt Schaefer

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Genotype, Portal venous pressure, Gastroenterology, Polymorphism, Single Nucleotide, Hepatic Decompensation in Portal Hypertension, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hypertension, Portal, medicine, Humans, Pharmacology (medical), Genetic Predisposition to Disease, Longitudinal Studies, Survival rate, Aged, Retrospective Studies, Hepatology, business.industry, Fatty liver, Membrane Proteins, Hepatitis C, Lipase, Hepatitis C, Chronic, Middle Aged, medicine.disease, Hepatic stellate cell activation, Fatty Liver, Survival Rate, 030104 developmental biology, Cross-Sectional Studies, Portal hypertension, 030211 gastroenterology & hepatology, Female, Original Article, Steatosis, business, Viral hepatitis, Liver Failure
Abstract

Background The rs738409 C>G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis. Aim To investigate its impact on hepatic decompensation and (liver-related) mortality in patients who had already developed portal hypertension. Moreover, we assessed its link with hepatic steatosis as evaluated by controlled attenuation parameter. Methods We performed a retrospective analysis in prospectively characterised patients with viral hepatitis/fatty liver disease-induced portal hypertension (hepatic venous pressure gradient [HVPG] ≥ 6 mm Hg) diagnosed at the Medical University of Vienna who underwent HVPG measurement (until 2013; n = 372; longitudinal study) or simultaneous HVPG and controlled attenuation parameter measurement (2014-2017; n = 153; cross-sectional study). Results While survival was similar between PNPLA3-C/C and -C/G patients, we observed substantially increased mortality in PNPLA3-G/G patients. PNPLA3-G/G had no impact on mortality in the subgroup of patients with viral hepatitis; however, we observed a strong independent association between PNPLA3-G/G and hepatic decompensation (adjusted subdistribution hazard ratio [aSHR]: 2.1, 95% confidence interval [95% CI]: 1.1-4; P = 0.024) as well as mortality (overall: aSHR: 2.2, 95% CI: 1.22-3.98; P = 0.009; liver-related: aSHR: 2.2, 95% CI: 1.08-4.46; P = 0.029) in patients with fatty liver disease. Interestingly, even in the subgroup of patients who had already progressed to clinically significant portal hypertension (HVPG ≥ 10 mm Hg), PNPLA3-G/G substantially increased mortality (aSHR: 2.33, 95% CI: 1.27-4.29; P = 0.006). PNPLA3-genotype had no influence on controlled attenuation parameter or the prevalence of values ≥248 dB/m. Conclusion PNPLA3-G/G-genotype seems to double the risks of hepatic decompensation and (liver-related) mortality in patients with portal hypertension due to fatty liver disease. Further studies are warranted to investigate potential underlying pathophysiological mechanisms unrelated to hepatic steatosis.

Published
2018

25. Heterozygous carriage of the alpha1-antitrypsin PiZ variant increases the risk to develop liver fibrosis

Author

Frank Lammert, Christian Trautwein, M. Trauner, Elmar Aigner, Thomas Berg, Clemens Schafmayer, Felix Stickel, Jochen Hampe, CV Heimes, M Gutberlet, Marcin Krawczyk, Karim Hamesch, Pierre Deltenre, Mattias Mandorfer, Janett Fischer, Stephan Buch, Pavel Strnad, Christian Datz, Marsha Y. Morgan, Sabina Janciauskiene, Michael Nothnagel, and Matthias C. Reichert

Subjects
medicine.medical_specialty, Carriage, business.industry, Internal medicine, Liver fibrosis, Gastroenterology, medicine, business
Published
2018

26. OC.04.7 LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PBC FROM THE POISE TRIAL GROUPED BIOCHEMICALLY BY RISK OF DISEASE PROGRESSION

Author

Elizabeth Smoot Malecha, Andreas E. Kremer, Alexander Liberman, M. Trauner, Frederik Nevens, Leigh MacConell, Christopher L. Bowlus, and A. Floreani

Subjects
medicine.medical_specialty, Hepatology, business.industry, Disease progression, Gastroenterology, Obeticholic acid, Term (time), chemistry.chemical_compound, chemistry, Internal medicine, Medicine, In patient, business
Published
2021

27. Cancer and hepatic steatosis

Author

Matthias Pinter, M. Trauner, Wolfgang Sieghart, and Rafael Paternostro

Subjects
Liver Cirrhosis, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, Review, Gastroenterology, Liver disease, Non-alcoholic Fatty Liver Disease, Internal medicine, cancer, Humans, Medicine, business.industry, hepatic steatosis, Liver Neoplasms, Fatty liver, Cancer, hepatocellular carcinoma, medicine.disease, digestive system diseases, Oncology, Hepatocellular carcinoma, chemotherapy-induced steatohepatitis, Steatosis, Steatohepatitis, business, Liver cancer
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent and increasing liver disease, which encompasses a variety of liver diseases of different severity. NAFLD can lead to liver cirrhosis with all its complications as well as hepatocellular carcinoma (HCC). Steatosis of the liver is not only related to obesity and other metabolic risk factors, but can also be caused by several drugs, including certain cytotoxic chemotherapeutic agents. In patients undergoing liver surgery, hepatic steatosis is associated with an increased risk of post-operative morbidity and mortality. This review paper summarizes implications of hepatic steatosis on the management of patients with cancer. Specifically, we discuss the epidemiological trends, pathophysiological mechanisms, and management of NAFLD, and its role as a leading cause of liver cancer. We elaborate on factors promoting immunosuppression in patients with NAFLD-related HCC and how this may affect the efficacy of immunotherapy. We also summarize the mechanisms and clinical course of chemotherapy-induced acute steatohepatitis (CASH) and its implications on cancer treatment, especially in patients undergoing liver resection., Highlights • Non-alcoholic fatty liver disease can lead to cirrhosis with all its complications, including hepatocellular carcinoma. • Chemotherapy-associated acute steatohepatitis is a side-effect of chemotherapeutic agents and may limit treatment options. • In this review we summarize current clinical concepts of NAFLD and CASH that help clinicians in their clinical practice.

Published
2021

28. Liver fibrosis assessment and treatment initiation within a systematic screening program among HIV/HIV-coinfected patients

Author

Florian J. Mayer, Markus Peck-Radosavljevic, Maximilian C. Aichelburg, Katharina Grabmeier-Pfistershammer, Robert Strassl, David Chromy, Mattias Mandorfer, M. Trauner, Theresa Bucsics, Philipp Schwabl, Thomas Reiberger, and Bernhard Scheiner

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Liver fibrosis, Gastroenterology, medicine, Physical therapy, Human immunodeficiency virus (HIV), business, medicine.disease_cause
Published
2017

29. ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis

Author

F Karnel, Maria Schoder, Theresa Bucsics, Philipp Schwabl, M. Trauner, Johanna Grünberger, J Karner, S Hoffmann, Arnulf Ferlitsch, Thomas Reiberger, Markus Peck-Radosavljevic, Wolfgang Matzek, and Mattias Mandorfer

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Gastroenterology, Albumin, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, Refractory ascites, business
Published
2017

30. Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease (NAFLD)

Author

P Munda, Christian Kienbacher, M. Trauner, Harald Hofer, M Wolzt, Emina Halilbasic, and Stefan Traussnigg

Subjects
Agonist, business.industry, medicine.drug_class, Fatty liver, Gastroenterology, Physiology, Non alcoholic, Disease, Pharmacology, medicine.disease, Non steroidal, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Medicine, 030211 gastroenterology & hepatology, In patient, Farnesoid X receptor, business
Published
2017

31. A prospective study to evaluate the efficacy of a standardized low calorie diet (HEPAFAST®) according to PNPLA3 genotype in patients with Non Alcoholic Fatty Liver Disease (NAFLD) – 2 months data (interim analysis)

Author

M. Trauner, Harald Hofer, B Meyer, Peter Ferenci, M Teufelhart, Thomas-Matthias Scherzer, B Mehl, S Nistler, Helmuth Haslacher, C Rabitsch, and R Winker

Subjects
medicine.medical_specialty, business.industry, Fatty liver, Gastroenterology, Non alcoholic, Disease, medicine.disease, Interim analysis, Internal medicine, Low calorie diet, Genotype, medicine, In patient, business, Prospective cohort study
Published
2017

32. Molecular effects of the soluble guanylyl cyclase stimulator Riociguat in experimental cirrhosis and impact on transaminases in patients

Author

F. Riedl, Douglas C. Bauer, Philipp Schwabl, Georg Oberhuber, Stefan Aschauer, Thomas Reiberger, M. Trauner, Philipp Königshofer, Hubert Hayden, Bruno K. Podesser, P Supper, Markus Peck-Radosavljevic, Ksenia Brusilovskaya, N. Rohr-Udilova, and Diana Bonderman

Subjects
Gerontology, business.industry, Gastroenterology, Medicine, In patient, Pharmacology, Soluble guanylyl cyclase, business, Riociguat, Experimental cirrhosis, medicine.drug
Published
2017

33. Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Extension with Obeticholic Acid in Austrian and German Patients with Primary Biliary Cholangitis

Author

M. Trauner, P Munda, E. Smoot Malecha, Leigh MacConell, Emina Halilbasic, Harald Hofer, and J. Owens-Grillo

Subjects
medicine.medical_specialty, business.industry, Gastroenterology, Obeticholic acid, medicine.disease, language.human_language, German, chemistry.chemical_compound, Cholestasis, chemistry, Internal medicine, language, Medicine, Open label, business
Published
2017

34. Anticoagulation in non-malignant portal vein thrombosis is associated with improved hepatic function

Author

Philipp Schwabl, K Lampichler, M. Trauner, Bernhard Scheiner, Arnulf Ferlitsch, Mattias Mandorfer, Thomas Reiberger, Cihan Ay, J Thaler, P Stammet, Ahmed Ba-Ssalamah, A. Brichta, Ingrid Pabinger, S Pokorny, and T Bucsics

Subjects
Hepatic function, medicine.medical_specialty, business.industry, Portal venous pressure, Gastroenterology, medicine, Non malignant, Radiology, business, medicine.disease, Portal vein thrombosis
Published
2017

35. Dynamics of occurrence of refractory coeliac disease and associated complications over 25 years

Author

W. Eigner, Christian Primas, K Bashir, Lili Kazemi-Shirazi, M. Trauner, Fritz Wrba, and Harald Vogelsang

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Cancer, Disease, medicine.disease, Coeliac disease, Lymphoma, Surgery, 03 medical and health sciences, 0302 clinical medicine, Refractory, 030220 oncology & carcinogenesis, Internal medicine, medicine, Adenocarcinoma, 030211 gastroenterology & hepatology, Pharmacology (medical), Enteropathy, business, Survival rate
Abstract

SummaryBackground Refractory coeliac disease, enteropathy associated T-cell lymphoma and small bowel adenocarcinoma are rare but prognostically important complications in coeliac disease. Aim To analyse potential changes in occurrence of complicated coeliac disease over the last 25 years. Methods One thousand one hundred and thirty eight patients were included and evaluated based on their time of first presentation at the Medical University of Vienna, Austria. Occurrences of refractory coeliac disease and associated malignancies were evaluated for 5-year intervals from January 1990 until December 2014 and were compared over time. Results 2.6% (n = 29) were diagnosed with refractory coeliac disease (females 65.6%, mean age at diagnosis 62.8 years). The proportion of those patients was 2.6%, 3.1%, 3.3%, 2.7% and 0.5% for the 5 year intervals from 1990 onwards. Thus, the number of refractory cases has been decreasing since 2000 (P = 0.024). The number of patients presenting with lymphoma (n = 7) was 0.6%, 0.4%, 1.1%, 0.8% and 0% from 1990 to 2014. Similarly the number of patients with adenocarcinoma (n = 4) decreased to 0% until 2014. Overall mortality in patients suffering from refractory disease was 48%. Of all patients diagnosed with lymphoma 71.4% died with a 5-year survival rate of 28.6%. Conclusions Over the past 15 years the occurrence of complicated coeliac disease has been decreasing. This possibly reflects a higher awareness of coeliac disease and optimised diagnosis and treatment with avoidance of long-term immunological disease activity. Symptomatic disease and a delay in diagnosis are risk factors for refractory coeliac disease and related cancer.

Published
2016

36. Prevalence of non-alcoholic fatty liver disease (NAFLD) among HIV+ individuals in Vienna

Author

Armin Rieger, Caroline Schmidbauer, M. Trauner, Bernhard Scheiner, M Gschwantler, Benedikt Simbrunner, Victor Schmidbauer, Mattias Mandorfer, Thomas Reiberger, David Chromy, Theresa Bucsics, Philipp Schwabl, Heidemarie Holzmann, and Rafael Paternostro

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Fatty liver, medicine, Human immunodeficiency virus (HIV), Non alcoholic, Disease, medicine.disease, medicine.disease_cause, business, Gastroenterology
Published
2019

38. PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort

Author

Bernhard Scheiner, F. Hucke, Fabian Finkelmeier, Joerg Trojan, Thomas Reiberger, Fredrik Waneck, Matthias Pinter, M. Trauner, J von Felden, Kornelius Schulze, Philipp Schwabl, Sandra Koch, Arndt Vogel, Markus Peck-Radosavljevic, Oliver Waidmann, Martha M. Kirstein, Christian Müller, Wolfgang Sieghart, Jan B. Hinrichs, Arndt Weinmann, and Henning Wege

Subjects
Oncology, medicine.medical_specialty, business.industry, Hepatocellular carcinoma, Internal medicine, Cohort, medicine, medicine.disease, business, Targeted immunotherapy
Published
2019

39. The HSD17B13:TA (rs72613567) splice variant protects against severity of non-alcoholic fatty liver disease but not fibrosis

Author

M. Trauner, P Munda, Stefan Traussnigg, Omar Keritam, Peter Ferenci, Judith Stift, Rafael Paternostro, Gerald W. Prager, Emina Halilbasic, Katharina Staufer, and AF Stättermayer

Subjects
medicine.medical_specialty, Fibrosis, business.industry, Internal medicine, Fatty liver, Alternative splicing, medicine, Non alcoholic, Disease, medicine.disease, business, Gastroenterology
Published
2019

41. The value of different CT-based methods for diagnosing sarcopenia and predicting mortality in patients with cirrhosis

Author

Katharina Lampichler, Thomas Reiberger, Mattias Mandorfer, C Landler, M. Trauner, Ulrika Asenbaum, Rafael Paternostro, Arnulf Ferlitsch, Constanze Bardach, and Remy Schwarzer

Subjects
medicine.medical_specialty, Cirrhosis, business.industry, Internal medicine, Sarcopenia, medicine, In patient, medicine.disease, business, Gastroenterology, Value (mathematics)
Published
2019

43. The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease

Author

Bernhard Scheiner, Gerda Leitner, Thomas Reiberger, M. Trauner, Patrick G. Northup, Johannes Thaler, Peter Quehenberger, Anselm B. Gruber, Cihan Ay, Ton Lisman, and Mattias Mandorfer

Subjects
medicine.medical_specialty, business.industry, ABO blood group system, Internal medicine, medicine, In patient, Chronic liver disease, medicine.disease, business, Gastroenterology, Portal vein thrombosis
Published
2019

47. Liver Fibrosis stage at baseline predicts outcome of metabolic surgery

Author

M Wakolbinger, Bernhard Ludvik, M. Trauner, Stefan Traussnigg, Karin Schindler, Tanja Würger, Gerald W. Prager, Christian Kienbacher, Renate Kruschitz, and Arnulf Ferlitsch

Subjects
medicine.medical_specialty, business.industry, Liver fibrosis, Internal medicine, Metabolic surgery, medicine, Stage (cooking), business, Baseline (configuration management), Outcome (game theory), Gastroenterology
Published
2019

48. Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension

Author

Bernhard Scheiner, Douglas C. Bauer, Peter Ferenci, AF Stättermayer, Benedikt Simbrunner, Matthias Pinter, Georg Semmler, Rafael Paternostro, Mattias Mandorfer, Thomas Reiberger, Theresa Bucsics, Philipp Schwabl, and M. Trauner

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Portal hypertension, Farnesoid X receptor, medicine.disease, business, Gastroenterology, Hepatic decompensation
Published
2019

49. COLORECTAL CANCER INCIDENCE AND THE PREVALENCE OF PRECURSOR LESIONS IN YOUNGER ADULTS

Author

A Asaturi, Irina Gessl, A Hinterberger, D Pammer, D Penz, Arnulf Ferlitsch, A Szymanska, B Majcher, Elisabeth Waldmann, Monika Ferlitsch, and M. Trauner

Subjects
medicine.medical_specialty, Younger adults, business.industry, Colorectal cancer, Internal medicine, Incidence (epidemiology), medicine, business, medicine.disease
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results